Sanofi-aventis introduces sanofi-aventis TV "A window on our company"
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has announced the launch of sanofi-aventis TV, a new webTV aimed at providing information about the company's wide range of patient-focused businesses, social responsibilities, and employee activities. The site will also provide perspectives on the company's mission and strategic directions.
Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer
- Details
- Category: Bayer
Bayer received approval in Japan for Nexavar® (sorafenib) tablets for the treatment of unresectable hepatocellular carcinoma (HCC) from the Ministry of Health, Labour and Welfare (MHLW). Nexavar, an oral anti-cancer drug, jointly developed by Bayer HealthCare AG and Onyx Pharmaceuticals, Inc., is the only drug therapy shown to significantly improve overall survival in patients with the disease.
Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management
- Details
- Category: Eli Lilly and Company
Two of the most recognized names in diabetes management - Eli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) - announced a strategic marketing collaboration to bolster each company's commitment to help people with diabetes manage their blood sugar using insulin therapy.
New data to be presented on Abbott's market-leading XIENCE V(R) stent
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced the company's schedule of major events and news announcements during EuroPCR 2009 in Barcelona, May 19 - 22. These include the presentation of new data from the SPIRIT V post-approval, single-arm study of the company's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System, as well as new details of Abbott's next-generation drug eluting stent in development,
the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System.
GlaxoSmithKline update: A (H1N1) influenza vaccine development
- Details
- Category: GlaxoSmithKline
GSK is committed to supporting governments and health authorities around the world to respond to the emergence of the new A (H1N1) influenza strain. Since the outbreak, the company has been in continuous discussions with governments and public health authorities, including the WHO, the US Centers for Disease Control and Prevention, the US Department of Health and Human Services and the European Centre for Disease Prevention and Control to help develop appropriate options to respond to the emergence of the new A (H1N1) influenza strain.
Novartis receives approval from FDA to market Prevacid®
- Details
- Category: Novartis
Novartis announced today that Prevacid® 24HR (lansoprazole delayed-release capsules 15 mg) has been approved by the US Food and Drug Administration (FDA) as the first over-the-counter (OTC) Proton Pump Inhibitor (PPI) for the treatment of frequent heartburn since 2003. Prevacid 24HR is expected to be available over-the-counter in 2009.
Pfizer Launches Free Medicines Program For Newly Unemployed Americans
- Details
- Category: Pfizer
Pfizer Inc will launch an innovative program to help eligible unemployed Americans and their families who have lost their health insurance maintain access to their Pfizer medicines for free. The inspiration for the new program, called MAINTAIN™ (Medicines Assistance for Those who Are in Need), was generated by Pfizer employees who were witnessing friends, family and neighbors struggle to make ends meet after losing their jobs.
More Pharma News ...
- Qlaira® - innovative estradiol-based oral contraceptive available in Europe
- Boehringer Ingelheim and DeveloGen AG announce agreement
- Roche provides additional donation of 5.65 million packs of Tamiflu to WHO
- Sanofi-aventis builds a New Vaccine Manufacturing Facility in France
- AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA
- Novo Nordisk reaches settlements regarding Oil-for-Food activities
- Nycomed files European marketing authorisation application for Daxas®